Table 2.

Development of person-time with viral suppression and viremia among all diagnosed PLHIV in the cohorts, including ART-naïve and treated person-time between 1999 and 2018 based on our longitudinal model

All diagnosed people living with HIV
Year	Viral suppression (< 50)	50 - < 200	200 - < 500	500 - < 1000	1000 - < 10,000	10,000 - < 100,000	100,000 - < 1.000000	> 1000,000
1999	22.2	9.1	7.4	4.8	18.2	24.5	12.8	0.8
2000	39.0	8.4	5.5	3.8	13.8	20.7	8.4	0.3
2001	45.0	7.2	4.3	3.2	13.8	18.2	7.9	0.3
2002	46.7	6.7	4.1	2.9	12.6	19.2	7.6	0.2
2003	50.8	6.0	3.2	2.2	11.3	17.9	8.2	0.4
2004	50.6	6.4	3.1	2.2	10.7	18.7	8.1	0.3
2005	52.8	6.3	3.0	2.3	10.6	17.9	6.9	0.3
2006	55.5	6.4	3.0	2.1	10.7	16.7	5.3	0.3
2007	58.1	6.7	2.7	2.0	9.7	15.9	4.5	0.3
2008	62.0	6.5	2.6	1.8	9.0	13.3	4.6	0.3
2009	65.3	6.2	2.2	1.6	7.7	12.8	4.1	0.3
2010	68.7	6.5	2.2	1.5	6.5	11.2	3.2	0.2
2011	73.2	6.6	2.0	1.3	5.4	8.7	2.6	0.2
2012	75.6	6.2	2.0	1.2	5.0	7.5	2.3	0.2
2013	78.6	5.8	1.8	1.1	4.2	6.3	2.1	0.2
2014	83.6	4.8	1.3	0.9	3.3	4.9	1.1	0.1
2015 a	86.7 a	3.8 a	1.1	0.8	2.8	3.8	0.9	0.1
2016	88.3	4.4	1.0	0.7	2.3	2.4	0.9	0.1
2017 b	91.3 b	3.7	0.8	0.5	1.5	1.5	0.6	0.1
2018	92.3	3.3	0.8	0.4	1.2	1.2	0.6	0.1

^a The UNAIDS target of viral suppression with VL < 200 copies/ml has been met for all diagnosed PLHIV in the study population in Germany since 2015

^b The UNAIDS target of viral suppression with VL < 50 copies/ml has been met for all diagnosed PLHIV in the study population in Germany since 2017